Tags

Type your tag names separated by a space and hit enter

Whole soy, but not purified daidzein, had a favorable effect on improvement of cardiovascular risks: a 6-month randomized, double-blind, and placebo-controlled trial in equol-producing postmenopausal women.
Mol Nutr Food Res 2014; 58(4):709-17MN

Abstract

SCOPE

Equol is produced by the intestinal bacteria from isoflavone daidzein. Studies have reported the health benefits of soy can only present or more pronounced in equol producers. This 6-month randomized controlled trial examined the effect of whole soy (soy flour) and purified daidzein on cardiovascular biomarkers and carotid intima-media thickness (CIMT) in prehypertensive postmenopausal women who were equol producers.

METHODS AND RESULTS

Two hundred seventy eligible women were randomized to either one of the three treatments: 40 g soy flour (whole soy group), 40 g low-fat milk powder + 63 mg daidzein (daidzein group), or 40 g low-fat milk powder (placebo group) daily each for 6 months. Fasting venous samples were obtained at baseline and end of trial for testing glucose, lipids, high sensitivity C-reactive protein (hs-CRP), and free fatty acid. Changes in common CIMT were also assessed. Serum LDL-C decreased by 7.95% (95% CI: -15.09∼-0.81%) and 6.32% (95% CI: -13.45∼0.08%), and serum hs-CRP decreased by 0.164 (95% CI: -0.309∼-0.019) and 0.054 (95% CI: -0.199∼0.012) in the whole soy group compared with daidzein and milk placebo groups, respectively. No significant change in CIMT was found.

CONCLUSION

Whole soy, but not purified daidzein, had a beneficial effect on reduction of LDL-C and hs-CRP among prehypertensive equol-producing postmenopausal women.

Authors+Show Affiliations

Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Shatin, NT, Hong Kong SAR, China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

24273218

Citation

Liu, Zhao-Min, et al. "Whole Soy, but Not Purified Daidzein, Had a Favorable Effect On Improvement of Cardiovascular Risks: a 6-month Randomized, Double-blind, and Placebo-controlled Trial in Equol-producing Postmenopausal Women." Molecular Nutrition & Food Research, vol. 58, no. 4, 2014, pp. 709-17.
Liu ZM, Ho SC, Chen YM, et al. Whole soy, but not purified daidzein, had a favorable effect on improvement of cardiovascular risks: a 6-month randomized, double-blind, and placebo-controlled trial in equol-producing postmenopausal women. Mol Nutr Food Res. 2014;58(4):709-17.
Liu, Z. M., Ho, S. C., Chen, Y. M., Ho, S., To, K., Tomlinson, B., & Woo, J. (2014). Whole soy, but not purified daidzein, had a favorable effect on improvement of cardiovascular risks: a 6-month randomized, double-blind, and placebo-controlled trial in equol-producing postmenopausal women. Molecular Nutrition & Food Research, 58(4), pp. 709-17. doi:10.1002/mnfr.201300499.
Liu ZM, et al. Whole Soy, but Not Purified Daidzein, Had a Favorable Effect On Improvement of Cardiovascular Risks: a 6-month Randomized, Double-blind, and Placebo-controlled Trial in Equol-producing Postmenopausal Women. Mol Nutr Food Res. 2014;58(4):709-17. PubMed PMID: 24273218.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Whole soy, but not purified daidzein, had a favorable effect on improvement of cardiovascular risks: a 6-month randomized, double-blind, and placebo-controlled trial in equol-producing postmenopausal women. AU - Liu,Zhao-Min, AU - Ho,Suzanne C, AU - Chen,Yu-Ming, AU - Ho,Stella, AU - To,Kenneth, AU - Tomlinson,Brian, AU - Woo,Jean, Y1 - 2013/11/24/ PY - 2013/07/10/received PY - 2013/08/22/revised PY - 2013/08/26/accepted PY - 2013/11/26/entrez PY - 2013/11/26/pubmed PY - 2015/11/3/medline KW - Cardiovascular risks KW - Daidzein KW - Inflammatory marker KW - Lipids KW - Whole soy SP - 709 EP - 17 JF - Molecular nutrition & food research JO - Mol Nutr Food Res VL - 58 IS - 4 N2 - SCOPE: Equol is produced by the intestinal bacteria from isoflavone daidzein. Studies have reported the health benefits of soy can only present or more pronounced in equol producers. This 6-month randomized controlled trial examined the effect of whole soy (soy flour) and purified daidzein on cardiovascular biomarkers and carotid intima-media thickness (CIMT) in prehypertensive postmenopausal women who were equol producers. METHODS AND RESULTS: Two hundred seventy eligible women were randomized to either one of the three treatments: 40 g soy flour (whole soy group), 40 g low-fat milk powder + 63 mg daidzein (daidzein group), or 40 g low-fat milk powder (placebo group) daily each for 6 months. Fasting venous samples were obtained at baseline and end of trial for testing glucose, lipids, high sensitivity C-reactive protein (hs-CRP), and free fatty acid. Changes in common CIMT were also assessed. Serum LDL-C decreased by 7.95% (95% CI: -15.09∼-0.81%) and 6.32% (95% CI: -13.45∼0.08%), and serum hs-CRP decreased by 0.164 (95% CI: -0.309∼-0.019) and 0.054 (95% CI: -0.199∼0.012) in the whole soy group compared with daidzein and milk placebo groups, respectively. No significant change in CIMT was found. CONCLUSION: Whole soy, but not purified daidzein, had a beneficial effect on reduction of LDL-C and hs-CRP among prehypertensive equol-producing postmenopausal women. SN - 1613-4133 UR - https://www.unboundmedicine.com/medline/citation/24273218/Whole_soy_but_not_purified_daidzein_had_a_favorable_effect_on_improvement_of_cardiovascular_risks:_a_6_month_randomized_double_blind_and_placebo_controlled_trial_in_equol_producing_postmenopausal_women_ L2 - https://doi.org/10.1002/mnfr.201300499 DB - PRIME DP - Unbound Medicine ER -